Literature DB >> 26583838

Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension).

M Beghetti1, I Schulze-Neick2, R M F Berger3, D D Ivy4, D Bonnet5, R G Weintraub6, T Saji7, D Yung8, G B Mallory9, R Geiger10, J T Berger11, R J Barst12, T Humpl13.   

Abstract

BACKGROUND: The TOPP Registry has been designed to provide epidemiologic, diagnostic, clinical, and outcome data on children with pulmonary hypertension (PH) confirmed by heart catheterisation (HC). This study aims to identify important characteristics of the haemodynamic profile at diagnosis and HC complications of paediatric patients presenting with PH. METHODS AND
RESULTS: HC data sets underwent a blinded review for confirmation of PH (defined as mean pulmonary arterial pressure ≥ 25 mmHg, pulmonary capillary wedge pressure ≤ 12 mmHg and pulmonary vascular resistance index [PVRI] of >3 WU × m(2)). Of 568 patients enrolled, 472 who fulfilled the inclusion criteria and had sufficient data from HC were analysed. A total of 908 diagnostic and follow-up HCs were performed and complications occurred in 5.9% of all HCs including five (0.6%) deaths. General anaesthesia (GA) was used in 53%, and conscious sedation in 47%. Complications at diagnosis were more likely to occur if GA was used (p=0.04) and with higher functional class (p=0.02). Mean cardiac index (CI) was within normal limits at diagnosis when analysed for the entire group (3.7 L/min/m(2); 95% confidence interval 3.4-4.1), as was right atrial pressure despite a severely increased PVRI (16.6 WU × m(2,) 95% confidence interval 15.6-17.76). However, 24% of the patients had a CI of <2.5L/min/m(2) at diagnosis. A progressive increase in PVRI and decrease in CI was observed with age (p<0.001).
CONCLUSION: In TOPP, haemodynamic assessment was remarkable for preserved CI in the majority of patients despite severely elevated PVRI. HC-related complication incidence was 5.9%, and was associated with GA and higher functional class.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Catheterisation; Congenital; Heart defects; Hypertension; Paediatrics; Pulmonary

Mesh:

Year:  2015        PMID: 26583838     DOI: 10.1016/j.ijcard.2015.10.087

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  14 in total

1.  Pediatric Development of Bosentan Facilitated by Modeling and Simulation.

Authors:  Jochen Zisowsky; Martine Géhin; Andjela Kusic-Pajic; Andreas Krause; Maurice Beghetti; Jasper Dingemanse
Journal:  Paediatr Drugs       Date:  2017-04       Impact factor: 3.022

2.  Right ventricular-vascular coupling ratio in pediatric pulmonary arterial hypertension: A comparison between cardiac magnetic resonance and right heart catheterization measurements.

Authors:  K T N Breeman; M Dufva; M J Ploegstra; V Kheyfets; T P Willems; J Wigger; K S Hunter; D D Ivy; R M F Berger; U Truong
Journal:  Int J Cardiol       Date:  2019-05-10       Impact factor: 4.164

3.  Prognostic Value of Change in Cardiac Index After Prostacyclin Initiation in Pediatric Pulmonary Hypertension.

Authors:  Patrick D Evers; Paul J Critser; Michelle Cash; Melissa Magness; Russel Hirsch
Journal:  Pediatr Cardiol       Date:  2020-09-24       Impact factor: 1.655

4.  Pediatric and Adolescent Pulmonary Hypertension: What Is the Risk of Undergoing Invasive Hemodynamic Testing?

Authors:  Anudeep Jassal; Omer Cavus; Elisa A Bradley
Journal:  J Am Heart Assoc       Date:  2018-02-28       Impact factor: 5.501

5.  Pulmonary arterial hypertension in the USA: an epidemiological study in a large insured pediatric population.

Authors:  Lin Li; Susan Jick; Stefanie Breitenstein; Gemzel Hernandez; Alexander Michel; David Vizcaya
Journal:  Pulm Circ       Date:  2017-02-01       Impact factor: 3.017

6.  Risk Factors for Major Early Adverse Events Related to Cardiac Catheterization in Children and Young Adults With Pulmonary Hypertension: An Analysis of Data From the IMPACT (Improving Adult and Congenital Treatment) Registry.

Authors:  Michael L O'Byrne; Kevin F Kennedy; Joshua P Kanter; John T Berger; Andrew C Glatz
Journal:  J Am Heart Assoc       Date:  2018-02-28       Impact factor: 5.501

Review 7.  Diagnosis, Evaluation and Treatment of Pulmonary Arterial Hypertension in Children.

Authors:  Benjamin S Frank; D Dunbar Ivy
Journal:  Children (Basel)       Date:  2018-03-23

8.  Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management.

Authors:  Erika B Rosenzweig; Steven H Abman; Ian Adatia; Maurice Beghetti; Damien Bonnet; Sheila Haworth; D Dunbar Ivy; Rolf M F Berger
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

9.  New Strategies for the Conduct of Clinical Trials in Pediatric Pulmonary Arterial Hypertension: Outcome of a Multistakeholder Meeting With Patients, Academia, Industry, and Regulators, Held at the European Medicines Agency on Monday, June 12, 2017.

Authors:  Cécile Ollivier; Haihao Sun; Wayne Amchin; Maurice Beghetti; Rolf M F Berger; Stefanie Breitenstein; Christine Garnett; Ninna Gullberg; Patrik Hassel; Dunbar Ivy; Steven M Kawut; Agnes Klein; Catherine Lesage; Marek Migdal; Barbara Nije; Michal Odermarsky; James Strait; Pieter A de Graeff; Norman Stockbridge
Journal:  J Am Heart Assoc       Date:  2019-05-21       Impact factor: 5.501

10.  Commentary: Echocardiographic Evaluation of Pulmonary Pressures and Right Ventricular Function after Pediatric Cardiac Surgery: A Simple Approach for the Intensivist.

Authors:  Stefan Kurath-Koller; Sabrina Schweintzger; Martin Köestenberger
Journal:  Front Pediatr       Date:  2018-05-08       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.